TRANSCENTA-B

6628
0.6305.26% ( -0.035 )
Delay Closed: Nov 16, 16:08:11

Overview

TRANSCENTA-B (6628)

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of v...

Open
0.650
High
0.660
Low
0.620
Prev. Close
0.665
Volume
165.00K
Turnover
105.91K
Avg Price
0.642
Bid/Ask Ratio
23.08%
Amplitude
6.02%
52wk High
3.060
Volume Ratio
0.60
Turnover Ratio
0.04%
52wk Low
0.545
HK Mkt Cap
285.59M
Market CapHKD
285.59M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.410
EPSDynamic
-0.342
EPSStatic
--
BVPS
1.40
P/B
0.45
HK Shares
453.32M
Dividend YieldTTM
--
DividendTTM
--
Shares
453.32M
Min lot size
500
Currency
HKD

TRANSCENTA-B Analyst Rating

View more

Forecast & Rating

Oct 16, 2025
Price forecast
HK$14.362180.06%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Transcenta staged a recovery after morning weakness, hitting an intraday low of HKD 1.17 before rebounding to close at HKD 1.29, up 2.4% from yesterday's close of HKD 1.26. The rebound was driven by positive clinical data for Ozekibart, which targets a rare cancer treatment gap, and strengthened market confidence following Inhibrx's data supporting an FDA filing. Despite a 26.3% YoY decline in Q4 revenue to HKD 2.63 million, net loss narrowed 37.3% with EPS improving from -HKD 0.206 to -HKD 0.124. The stock remains 77.8% below its 52-week high of HKD 5.80 and trades below both the 20-day MA (HKD 1.35) and 60-day MA (HKD 1.92), with a YTD decline of 42.7%. However, recent share placements raising approximately HKD 59.34 million and grants of 451,500 employee share awards have alleviated liquidity concerns.

News